We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced that it has submitted a new drug application (NDA) to the FDA for JAK inhibitor candidate, filgotinib, for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). A priority review voucher was submitted with the NDA which should shorten the anticipated time for review. .
Shares of Gilead have gained 4.4% so far this year compared with the industry’s growth of 7.8%.
The NDA includes data from the phase III clinical program, FINCH, which comprises three studies. The data from the FINCH studies showed that filgotinib met its primary endpoints and demonstrated durable efficacy and safety results across multiple RA patient populations, including people with prior inadequate response to methotrexate treatment (MTX), those who were intolerant to one or more biologic treatments and those who were MTX treatment-naive. The safety results were consistent across the studies. These studies demonstrated an efficacy and tolerability profile of filgotinib that may offer meaningful improvements in RA treatment response for patients with this chronic disease.
In August, Gilead and partner Galapagos (GLPG - Free Report) announced that the European Medicines Agency (EMA) accepted their marketing authorization application (MAA) for filgotinib as a treatment for RA. The company has also filed a regulatory application in Japan for the same.
Notably, a potential approval of the candidate for RA and successful development in other inflammation indications are expected to favorably impact Gilead’s revenues, as the targeted indication has a significant market opportunity. However, filgotinib is likely to face competition from Eli Lilly’s (LLY - Free Report) Olumiant, which is already approved as a treatment for RA. Several other pharma companies are also developing drugs for inflammation indications, including RA.
Alkermes’ earnings per share estimates have increased from 36 cents to 52 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 236.80%, on average.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
Gilead Sciences, Inc. (GILD - Free Report) announced that it has submitted a new drug application (NDA) to the FDA for JAK inhibitor candidate, filgotinib, for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). A priority review voucher was submitted with the NDA which should shorten the anticipated time for review. .
Shares of Gilead have gained 4.4% so far this year compared with the industry’s growth of 7.8%.
The NDA includes data from the phase III clinical program, FINCH, which comprises three studies. The data from the FINCH studies showed that filgotinib met its primary endpoints and demonstrated durable efficacy and safety results across multiple RA patient populations, including people with prior inadequate response to methotrexate treatment (MTX), those who were intolerant to one or more biologic treatments and those who were MTX treatment-naive. The safety results were consistent across the studies. These studies demonstrated an efficacy and tolerability profile of filgotinib that may offer meaningful improvements in RA treatment response for patients with this chronic disease.
In August, Gilead and partner Galapagos (GLPG - Free Report) announced that the European Medicines Agency (EMA) accepted their marketing authorization application (MAA) for filgotinib as a treatment for RA. The company has also filed a regulatory application in Japan for the same.
Notably, a potential approval of the candidate for RA and successful development in other inflammation indications are expected to favorably impact Gilead’s revenues, as the targeted indication has a significant market opportunity. However, filgotinib is likely to face competition from Eli Lilly’s (LLY - Free Report) Olumiant, which is already approved as a treatment for RA. Several other pharma companies are also developing drugs for inflammation indications, including RA.
Gilead Sciences, Inc. Price
Gilead Sciences, Inc. price | Gilead Sciences, Inc. Quote
Zacks Rank & A Stock to Consider
Gilead currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Alkermes Plc. (ALKS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ earnings per share estimates have increased from 36 cents to 52 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 236.80%, on average.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>